Pretreatment with a dual antiplatelet and anticoagulant (APAC) reduces ischemia-reperfusion injury in a mouse model of temporary middle cerebral artery occlusion-implications for neurovascular procedures.
APAC
Anticoagulant
Antiplatelet
Cerebral ischemia
Infarct
Ischemia–reperfusion injury
Transient
Journal
Acta neurochirurgica
ISSN: 0942-0940
Titre abrégé: Acta Neurochir (Wien)
Pays: Austria
ID NLM: 0151000
Informations de publication
Date de publication:
15 Mar 2024
15 Mar 2024
Historique:
received:
05
12
2023
accepted:
14
02
2024
medline:
18
3
2024
pubmed:
15
3
2024
entrez:
15
3
2024
Statut:
epublish
Résumé
Several neurovascular procedures require temporary occlusion of cerebral arteries, leading to ischemia of unpredictable length, occasionally causing brain infarction. Experimental models of cerebral ischemia-reperfusion injury have established that platelet adhesion and coagulation play detrimental roles in reperfusion injury following transient cerebral ischemia. Therefore, in a model of cerebral ischemia-reperfusion injury (IRI), we investigated the therapeutic potential of a dual antiplatelet and anticoagulant (APAC) heparin proteoglycan mimetic which is able to bind to vascular injury sites. Brain ischemia was induced in mice by transient occlusion of the right middle cerebral artery for 60 min. APAC, unfractionated heparin (UFH) (both at heparin equivalent doses of 0.5 mg/kg), or vehicle was intravenously administered 10 min before or 60 min after the start of ischemia. At 24 h later, mice were scored for their neurological and motor behavior, and brain damage was quantified. Both APAC and UFH administered before the onset of ischemia reduced brain injury. APAC and UFH pretreated mice had better neurological and motor functions (p < 0.05 and p < 0.01, respectively) and had significantly reduced cerebral infarct sizes (p < 0.01 and p < 0.001, respectively) at 24 h after transient occlusion compared with vehicle-treated mice. Importantly, no macroscopic bleeding complications were observed in either APAC- or UFH-treated animals. However, when APAC or UFH was administered 60 min after the start of ischemia, the therapeutic effect was lost, but without hemorrhaging either. Pretreatment with APAC or UFH was safe and effective in reducing brain injury in a model of cerebral ischemia induced by transient middle cerebral artery occlusion. Further studies on the use of APAC to limit ischemic injury during temporary occlusion in neurovascular procedures are indicated.
Sections du résumé
BACKGROUND
BACKGROUND
Several neurovascular procedures require temporary occlusion of cerebral arteries, leading to ischemia of unpredictable length, occasionally causing brain infarction. Experimental models of cerebral ischemia-reperfusion injury have established that platelet adhesion and coagulation play detrimental roles in reperfusion injury following transient cerebral ischemia. Therefore, in a model of cerebral ischemia-reperfusion injury (IRI), we investigated the therapeutic potential of a dual antiplatelet and anticoagulant (APAC) heparin proteoglycan mimetic which is able to bind to vascular injury sites.
METHODS
METHODS
Brain ischemia was induced in mice by transient occlusion of the right middle cerebral artery for 60 min. APAC, unfractionated heparin (UFH) (both at heparin equivalent doses of 0.5 mg/kg), or vehicle was intravenously administered 10 min before or 60 min after the start of ischemia. At 24 h later, mice were scored for their neurological and motor behavior, and brain damage was quantified.
RESULTS
RESULTS
Both APAC and UFH administered before the onset of ischemia reduced brain injury. APAC and UFH pretreated mice had better neurological and motor functions (p < 0.05 and p < 0.01, respectively) and had significantly reduced cerebral infarct sizes (p < 0.01 and p < 0.001, respectively) at 24 h after transient occlusion compared with vehicle-treated mice. Importantly, no macroscopic bleeding complications were observed in either APAC- or UFH-treated animals. However, when APAC or UFH was administered 60 min after the start of ischemia, the therapeutic effect was lost, but without hemorrhaging either.
CONCLUSIONS
CONCLUSIONS
Pretreatment with APAC or UFH was safe and effective in reducing brain injury in a model of cerebral ischemia induced by transient middle cerebral artery occlusion. Further studies on the use of APAC to limit ischemic injury during temporary occlusion in neurovascular procedures are indicated.
Identifiants
pubmed: 38485848
doi: 10.1007/s00701-024-06017-x
pii: 10.1007/s00701-024-06017-x
pmc: PMC10940479
doi:
Substances chimiques
Anticoagulants
0
Heparin
9005-49-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
137Informations de copyright
© 2024. The Author(s).
Références
Blood. 1999 Dec 1;94(11):3829-38
pubmed: 10572098
Br J Surg. 2018 Jan;105(1):26-36
pubmed: 29205297
Neurosurgery. 2015 Mar;11 Suppl 2:3-7
pubmed: 25251196
Thromb Res. 2018 Sep;169:143-151
pubmed: 30071479
J Am Heart Assoc. 2018 Mar 1;7(5):
pubmed: 29496683
Arterioscler Thromb Vasc Biol. 2000 Nov;20(11):E113-9
pubmed: 11073864
Eur J Radiol. 2013 Oct;82(10):1646-52
pubmed: 23523515
Stroke. 2011 Feb;42(2):380-8
pubmed: 21183750
Neurosurgery. 2006 Apr;58(4):612-8; discussion 612-8
pubmed: 16575324
J Cardiovasc Pharmacol. 2021 Sep 1;78(3):453-462
pubmed: 34132685
Clin Exp Nephrol. 2017 Jun;21(3):436-445
pubmed: 27405618
World Neurosurg. 2019 Jun;126:468-471
pubmed: 30898732
World Neurosurg. 2019 Jan;121:28-32
pubmed: 30261388
J Neurointerv Surg. 2019 Apr;11(4):362-366
pubmed: 30201813
Neurosurg Rev. 2019 Sep;42(3):649-661
pubmed: 29790066
Elife. 2019 Aug 22;8:
pubmed: 31436532
Int J Stroke. 2018 Oct;13(7):734-742
pubmed: 29543141
Thromb Res. 2023 Aug;228:163-171
pubmed: 37331119
Eur J Vasc Endovasc Surg. 2019 Dec;58(6):903-911
pubmed: 31708337
Stroke. 2016 Apr;47(4):1165-72
pubmed: 26786115
Stroke. 2016 Sep;47(9):2419-22
pubmed: 27470988
J Neurol Neurosurg Psychiatry. 2013 Jan;84(1):42-8
pubmed: 23012447
J Neurointerv Surg. 2020 Jan;12(1):33-37
pubmed: 31308199
Semin Thromb Hemost. 2014 Nov;40(8):837-44
pubmed: 25393636